Carbylan Therapeutics CEO T Crockett's 2023 pay falls 44% to $3.6M
Carbylan Therapeutics reports 2023 executive compensation
By ExecPay News
Published: August 14, 2023
Carbylan Therapeutics reported fiscal year 2023 executive compensation information on August 14, 2023.
In 2023, three executives at Carbylan Therapeutics received on average a compensation package of $2.6M, a 39% decrease compared to previous year.
Average pay of disclosed executives at Carbylan Therapeutics
T. Andrew Crockett, Chief Executive Officer, received $3.6M in total, which decreased by 44% compared to 2022. 62% of Crockett's compensation, or $2.3M, was in stock awards. Crockett also received $267K in bonus, $455K in option awards, $635K in salary, as well as $13K in other compensation.
Benjamin L. Palleiko, Chief Financial Officer, received a compensation package of $2.4M, which decreased by 29% compared to previous year. 63% of the compensation package, or $1.5M, was in stock awards.
Christopher M. Yea, Chief Development Officer, earned $1.7M in 2023, a 38% decrease compared to previous year.
Carbylan Therapeutics' fiscal year ends on April 30.
Related executives
You may also like
Source: SEC filing on August 14, 2023.